Moody's Ratings (Moody's) has completed a periodic review of the ratings of Southern Company Funding Corporation and Southern Elect Generating Co and other ratings that are associated with these issuers. The review was conducted through a rating committee held on 15 May 2024 in which Moody's reasse...
Nkarta Reports First Quarter 2024 Financial Results and Corporate Highlights Dosing of first patient with NKX019 for lupus nephritis using disease-tailored lymphodepletion expected in first half of 2024Cash balance of $450.0 million on March 31, 2024, including cash, cash equivalents and investmentsStrong balance sheet, bolstered by recent $240.1 million offering, expected to fund operations into late 2027 SOUTH SAN FRANCISCO, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell the...
ALX Oncology Reports First Quarter 2024 Financial Results and Provides Corporate Update SOUTH SAN FRANCISCO, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or the “Company”) (Nasdaq: ALXO), an immuno-oncology company developing therapies that block the CD47 immune checkpoint pathway, today reported financial results for the first quarter ended March 31, 2024, and provided a corporate update. “We entered the quarter with a great deal of momentum having achieved a key validating development milestone for our platform asset evorpacept in Q4 2023 by repo...
Vaxcyte Reports First Quarter 2024 Financial Results and Provides Business Update -- VAX-31 Adult Phase 1/2 Study Enrollment Completed; Topline Safety, Tolerability and Immunogenicity Data Expected in Third Quarter of 2024 -- -- Following VAX-31 Adult Phase 1/2 Study Readout, Vaxcyte to Advance VAX-24 or VAX-31 to Adult Phase 3 Program -- -- VAX-24 Infant Phase 2 Study Enrollment Completed; Topline Data from Primary Immunization Series Expected by End of First Quarter of 2025, Followed by Topline Data from Booster Dose by End of 2025 -- -- $1.9 Billion in Cash, Cash Equivalents and Inves...
Two Directors at Kellanova Co sold 87,600 shares at between 60.052USD and 60.923USD. The significance rating of the trade was 70/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the las...
A director at Entergy Corp sold/sold after exercising options 9,229 shares at 108.708USD and the significance rating of the trade was 83/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over...
LINCOLN, Neb.--(BUSINESS WIRE)-- National Research Corporation, dba NRC Health, (NASDAQ:NRC) today announced results for the first quarter 2024. CEO Commentary Michael Hays, Chief Executive Officer, commented: “NRC continues to be strongly positioned for growth in our expanding markets. Our decades of benchmarks and trusted thought leadership afford healthcare insights unavailable to most competitors, while our client service remains unmatched, and we continue to roll out innovative new products and technologies. Our mission to enhance outcomes and experiences for everyone in the healthcar...
ALX Oncology Appoints Allison Dillon as Chief Business Officer SOUTH SAN FRANCISCO, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or “the Company”) (Nasdaq: ALXO), an immuno-oncology company developing therapies that block the CD47 immune checkpoint pathway, today announced the appointment of Allison Dillon, Ph.D., as Chief Business Officer (“CBO”). “We are excited to welcome Allison to our leadership team in the midst of this promising growth period for our Company,” said Jason Lettmann, Chief Executive Officer of ALX Oncology. “For over 15 yea...
Moody's Ratings (Moody's) today assigned a Baa2 rating to Kellanova's proposed €300 million of 10-year senior unsecured notes. Kellanova's Baa2 senior unsecured ratings and Prime-2 commercial paper rating remains unchanged. The outlook is stable. Kellanova will utilize the net proceeds for general...
Moody's Ratings (Moody's) today assigned a Baa2 rating to Kellanova's ("Kellanova") proposed $300 million of 30-year senior unsecured notes. Kellanova's Baa2 senior unsecured ratings and Prime-2 commercial paper rating remains unchanged. The outlook is maintained at stable. Kellanova will utilize ...
A director at Southern Co sold 20,000 shares at 75.024USD and the significance rating of the trade was 72/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly sho...
Two Directors at Kimberly Clark Corp sold/sold after exercising options 14,168 shares at between 135.240USD and 135.527USD. The significance rating of the trade was 80/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by a...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.